Sage Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders.
Sage Therapeutics stock last closed at $19.27, up 0.84% from the previous day, and has decreased 49.18% in one year. It has underperformed other stocks in the Biotechnology industry by 0.21 percentage points. Sage Therapeutics stock is currently +16.68% from its 52-week low of $16.52, and -67.88% from its 52-week high of $59.99.
There are currently 59.97M shares of SAGE outstanding. The market capitalization of SAGE is $1.16B. In the past 24 hours, 746,131 SAGE shares were traded.
You will need a brokerage account to access the NASDAQ market and buy SAGE shares.
Based on our experience, eToro is the best stock brokerage. eToro gives you:
Get $10 towards your share purchase by signing up for an account with eToro today.Open eToro Account
Now that you've chosen the right brokerage, the next step is to fill out some personal info so you are able to buy SAGE stock today.
Now that you've finished signing up on the best free stock trading app, you need to deposit funds:
Check out the tutorial below for more details depositing money into your new brokerage account.
After you have chosen the best place to buy Sage Therapeutics stock, it's absolutely critical to analyze their stock before you buy, so you truly comprehend the risk as well as the opportunity.
WallStreetZen was created to help average investors do more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on SAGE's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge SAGE's true value.
Using relative valuations metrics:
You can access additional valuation research on SAGE's stock here.
Out of 14 Equities analysts who track SAGE, the consensus analyst rating on Sage Therapeutics is a Hold
Please keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Vikram Purohit, a bottom 8% analyst from Morgan Stanley maintains SAGE with a hold rating and lowers their SAGE price target from $49.00 to $20.00, on Aug 9, 2023.
Ritu Baral, a bottom 2% analyst from TD Cowen maintains SAGE with a buy rating and lowers their SAGE price target from $105.00 to $28.00, on Aug 8, 2023.
Jay Olson, a top 7% analyst from Oppenheimer maintains SAGE with a hold rating and lowers their SAGE price target from $24.00 to $20.00, on Aug 8, 2023.
Joon Lee, a bottom 34% analyst from Truist Securities maintains SAGE with a hold rating and lowers their SAGE price target from $40.00 to $20.00, on Aug 8, 2023.
Sumant Kulkarni, a bottom 8% analyst from Canaccord Genuity downgrades SAGE to a hold rating and lowers their SAGE price target from $64.00 to $21.00, on Aug 8, 2023.
Canaccord Genuity's Sumant Kulkarni downgraded their rating on Sage Therapeutics (NASDAQ: SAGE) from Strong Buy to Hold on 2023/08/08. The analyst also lowered their price target by 67.2% from $64 to $21.
In a note published following the release of the company's Q2 2023 print on 2023/08/07, the analyst said he made the moves to reflect the FDA's rejection of zuranolone for the treatment of major depressive disorder* (MDD) and "uncertainty resulting from this outcome."
"Fresh from this unfortunate outcome," management did not provide many details on a path forward in MDD during the earnings call other than to appeal the rejection using conventional channels, Kulkarni reported.
Looking ahead, besides zuranolone clinical-trial-related data, other catalysts are "some time off," the analyst noted.
* In an announcement on 2023/08/04, the FDA approved zuranolone for adults with postpartum depression (PPD) but denied it in the treatment of adults with major depressive disorder (MDD).
On 2023/08/07, Sage Therapeutics reported:
CEO Barry Greene commented: “We are currently at a tipping point with the burden and prevalence of brain health conditions accelerating at an alarming rate. The need has never been greater than it is today and our team is singularly focused on changing the trajectory of these devastating diseases through our development efforts and novel pipeline.
“We were delighted to receive U.S. Food and Drug Administration (FDA) approval for ZURZUVAE as the first-and-only oral treatment specifically indicated for adults with postpartum depression (PPD), the most common medical complication of childbirth. We believe the need for new treatment options for women with PPD is a significant medical need and presents a strong business opportunity.
"While we were very disappointed by the recent Complete Response Letter (CRL) we received from the FDA regarding zuranolone in the treatment of major depressive disorder (MDD), we are reviewing the feedback from the FDA and evaluating our next steps.”
“While we believe we are well capitalized, given the impact of the CRL for zuranolone in MDD on our plans, we are currently evaluating resource allocation, including pipeline prioritization and a workforce reorganization with a goal of extending our cash runway.
"With a right-sized organization and portfolio, we believe we have an opportunity to emerge as an even stronger company. We plan to provide greater detail and next steps before the end of Q3."
You can dig deeper into what analysts are saying on the Sage Therapeutics stock forecast page.
Last year, SAGE revenue was $11.35M. In the last five year, SAGE's revenue has grown by -33.91% per year. This was slower than the Biotechnology industry average of 35.68%.
Find out more about SAGE's earnings and revenue performance here.
Over the last 12 months, executives and large shareholders at SAGE have bought more shares than they have sold.
Elizabeth Barrett, Director of SAGE, was the latest SAGE insider to buy. They bought $37,278.00 worth of SAGE stock on Aug 9, 2023.
Dig into more about who owns SAGE stock here.
No, Sage Therapeutics doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
There are two main order types:
Press the Open Trade button and your broker will place your order.
If you want more help buying stocks on eToro, click the how to video below:
Now that you own some SAGE shares, you'll want to stay up-to-date on your stock purchase.
Create a watchlist to track your SAGE stock.
To summarize, here are the 6 steps to buy stock in Sage Therapeutics:
If you need a online brokerage, eToro is our favorite option.Get Started with eToro Today
If you want to keep track of your new investment in Sage Therapeutics, create your watchlist below.
How much does it cost to buy one Sage Therapeutics share?
Is now a good time to buy Sage Therapeutics stock?
What is the best way to buy Sage Therapeutics stock?